Response to Crizotinib in Fusion-Positive Intrahepatic Cholangiocarcinoma

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2022 Jan 20

PMID 35050759

Authors

Christopher D Jakubowski

Aditya A Mohan

Ihab R Kamel

Mark Yarchoan

Affiliations

Soon will be listed here.

Citing Articles

Tumour-agnostic kinase inhibitors.

Adashek J, Nikanjam M, Kurzrock R Nat Rev Drug Discov. 2025; .

PMID: 40050521 DOI: 10.1038/s41573-025-01147-y.

Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.

Plum P, Hess T, Bertrand D, Morgenstern I, Velazquez Camacho O, Jonas C Clin Transl Med. 2024; 14(6):e1723.

PMID: 38877653 PMC: 11178519. DOI: 10.1002/ctm2.1723.

Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.

Li S, Zhang H, Chen T, Zhang X, Shang G Cancer Med. 2024; 13(8):e7201.

PMID: 38629293 PMC: 11022151. DOI: 10.1002/cam4.7201.

Molecular Analysis of Biliary Tract Cancers with the Custom 3' RACE-Based NGS Panel.

Mitiushkina N, Tiurin V, Anuskina A, Bordovskaya N, Shestakova A, Martianov A Diagnostics (Basel). 2023; 13(20).

PMID: 37891989 PMC: 10605186. DOI: 10.3390/diagnostics13203168.

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.

Mody K, Jain P, El-Refai S, Azad N, Zabransky D, Baretti M JCO Precis Oncol. 2022; 6:e2100510.

PMID: 35675577 PMC: 9200391. DOI: 10.1200/PO.21.00510.

References

Roskoski Jr R . ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Pharmacol Res. 2017; 121:202-212. DOI: 10.1016/j.phrs.2017.04.022. View

Lee K, Lee K, Kim T, Han S, Oh D, Im S . Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma. BMC Cancer. 2015; 15:721. PMC: 4609147. DOI: 10.1186/s12885-015-1737-4. View

Peraldo Neia C, Cavalloni G, Balsamo A, Venesio T, Napoli F, Sassi F . Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR. Genes Chromosomes Cancer. 2014; 53(12):1033-40. DOI: 10.1002/gcc.22212. View

Shaw A, Ou S, Bang Y, Camidge D, Solomon B, Salgia R . Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 371(21):1963-71. PMC: 4264527. DOI: 10.1056/NEJMoa1406766. View

Subbiah V, Hong D, Meric-Bernstam F . Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report. Proc Natl Acad Sci U S A. 2016; 113(11):E1419-20. PMC: 4801313. DOI: 10.1073/pnas.1522052113. View

Couts K, McCoach C, Murphy D, Christiansen J, Turner J, Lewis K . Acral Lentiginous Melanoma Harboring a Gene Fusion With Clinical Response to Entrectinib. JCO Precis Oncol. 2022; 1:1-7. DOI: 10.1200/PO.16.00013. View

Liu P, Wu Y, Sun L, Zuo Q, Shi M . ROS kinase fusions are not common in Chinese patients with cholangiocarcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 2013; 33(4):474-8. View

Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y, Shimada Y . ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol. 2013; 37(4):554-62. DOI: 10.1097/PAS.0b013e3182758fe6. View

Abou-Alfa G, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R . Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020; 21(5):671-684. PMC: 8461541. DOI: 10.1016/S1470-2045(20)30109-1. View

10.

Shaw A, Felip E, Bauer T, Besse B, Navarro A, Postel-Vinay S . Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017; 18(12):1590-1599. PMC: 5777233. DOI: 10.1016/S1470-2045(17)30680-0. View

11.

Chiang N, Hsu C, Chen J, Tsou H, Shen Y, Chao Y . Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. Sci Rep. 2016; 6:25369. PMC: 4853728. DOI: 10.1038/srep25369. View

12.

Lee H, Seol H, Kim J, Chun S, Suh Y, Park Y . ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms. Ann Surg Oncol. 2012; 20(1):200-8. DOI: 10.1245/s10434-012-2553-6. View

13.

Graham R, Barr Fritcher E, Pestova E, Schulz J, Sitailo L, Vasmatzis G . Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014; 45(8):1630-8. DOI: 10.1016/j.humpath.2014.03.014. View

14.

Kwak E, Bang Y, Camidge D, Shaw A, Solomon B, Maki R . Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363(18):1693-703. PMC: 3014291. DOI: 10.1056/NEJMoa1006448. View

15.

Abou-Alfa G, Macarulla T, Javle M, Kelley R, Lubner S, Adeva J . Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(6):796-807. PMC: 7523268. DOI: 10.1016/S1470-2045(20)30157-1. View

16.

Saborowski A, Saborowski M, Davare M, Druker B, Klimstra D, Lowe S . Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci U S A. 2013; 110(48):19513-8. PMC: 3845141. DOI: 10.1073/pnas.1311707110. View

17.

Drilon A, Siena S, Ou S, Patel M, Ahn M, Lee J . Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017; 7(4):400-409. PMC: 5380583. DOI: 10.1158/2159-8290.CD-16-1237. View

18.

Uguen A, De Braekeleer M . ROS1 fusions in cancer: a review. Future Oncol. 2016; 12(16):1911-28. DOI: 10.2217/fon-2016-0050. View

19.

Bergethon K, Shaw A, Ou S, Katayama R, Lovly C, McDonald N . ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012; 30(8):863-70. PMC: 3295572. DOI: 10.1200/JCO.2011.35.6345. View

20.

Mescam-Mancini L, Lantuejoul S, Moro-Sibilot D, Rouquette I, Souquet P, Audigier-Valette C . On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer. 2014; 83(2):168-73. DOI: 10.1016/j.lungcan.2013.11.019. View